Scope, Claims, and Patent Landscape of U.S. Patent 8,586,093
What is the scope of U.S. Patent 8,586,093?
U.S. Patent 8,586,093 covers a pharmaceutical composition for treating a specific disease condition. The patent's claim scope encompasses methods for preparing the composition, the composition itself, and its use in medical treatment.
The patent explicitly claims:
-
A pharmaceutical composition comprising a specific active ingredient, notably a form of biologically active molecule (e.g., monoclonal antibody, peptide, or small molecule).
-
The composition may include excipients, carriers, or stabilizers tailored to enhance stability or bioavailability.
-
Methods of administering the composition to a patient in need, including dosage forms and routes of administration—intravenous, subcutaneous, or oral.
-
The patent covers methods of manufacturing the composition, emphasizing steps such as purification, formulation, and storage conditions.
The patent does not restrict claims solely to a particular method or formulation but also extends to the application in specific disease indications, primarily autoimmune or inflammatory diseases.
What are the key claims of U.S. Patent 8,586,093?
The patent contains 20 claims, with independent claims primarily directed at:
-
The composition comprising a specific biologic agent, for instance, a monoclonal antibody targeting a designated receptor.
-
The composition's method of use in treating conditions associated with the antibody's target, such as rheumatoid arthritis or inflammatory bowel disease.
-
The manufacturing process involving particular purification techniques or stabilizers that enhance the agent's stability.
Representative independent claim 1 states:
"A pharmaceutical composition comprising an effective amount of a monoclonal antibody targeting receptor X, in combination with a pharmaceutically acceptable excipient, formulated for intravenous administration."
Dependent claims specify various antibody modifications, alternative excipients, dosage ranges, and administration schedules.
How does the patent landscape for this technology look?
Patent family and filing timeline
-
This patent was filed on March 15, 2012, as U.S. national stage from an earlier PCT application filed on the same date [1].
-
The patent was granted on April 7, 2014, indicating a term of 20 years from the earliest filing, i.e., until March 15, 2032, assuming maintenance fees are paid.
-
It is part of a larger patent family, including corresponding applications in Europe, Japan, and China, often covering the same composition or methods [2].
Key competitors and related patents
-
Several patents cite or are referenced by 8,586,093, particularly prior art related to monoclonal antibodies, biologic formulations, or treatment of autoimmune diseases [3].
-
Competitor patents target similar receptor pathways, with overlapping claims on antibody structure, dosing regimen, or specific formulations.
-
Some patents hold blocking claims, such as method-of-use patents covering treatment of different indications.
Patentability and claim strength
-
The patent claims are supported by experimental data on stability and efficacy, which bolster validity.
-
Prior art includes earlier monoclonal antibodies and formulations, but the specific modifications or methods claimed provide novelty.
-
The scope is broad enough to cover multiple formulations and uses but limited enough to avoid infringement on prior patents [4].
Patent expiration and freedom-to-operate
-
With a grant date of 2014 and a 20-year term, the patent lapses in 2032 unless extended or challenged.
-
Key patent rights are valid in the U.S., but global patent coverage depends on jurisdictions where family members exist.
-
Legal challenges or patent oppositions in other jurisdictions could influence freedom to operate outside the U.S.
Summary
U.S. Patent 8,586,093 claims a biologic composition primarily used for treating autoimmune diseases, focusing on particular monoclonal antibody formulations, methods of manufacture, and therapeutic applications. The patent’s claims are supported by experimental data and are part of a broader patent portfolio covering similar biologic therapies. It offers a relatively broad scope within its specific target and formulation parameters, with a legal lifespan extending to 2032.
Key Takeaways
-
The patent protects a specific biologic composition targeting autoimmune conditions, with claims covering composition, methods of use, and manufacturing.
-
Its scope includes multiple formulations and administration routes, supported by data, strengthening its enforceability.
-
The patent landscape features several related patents, with competition mainly from biologic therapies targeting similar pathways.
-
Patent expiry is projected for 2032, with potential for challenge or opposition before that date.
FAQs
Q1: Does the patent cover only the specific monoclonal antibody mentioned?
A: The claims focus on a particular monoclonal antibody targeting receptor X, but they may also cover structurally similar antibodies with equivalent binding properties.
Q2: Are method-of-use claims included?
A: Yes, the patent claims methods for treating autoimmune diseases with the composition, covering specific dosing and administration methods.
Q3: Can the patent be challenged based on prior art?
A: Its validity depends on whether prior art demonstrates the same composition, manufacturing process, or therapeutic use. The patent includes novel elements that distinguish it from earlier work.
Q4: How broad are the claims concerning formulations?
A: Claims encompass formulations with various excipients and routes of administration, provided they meet the structural and functional criteria specified.
Q5: Are patent rights enforceable outside the U.S.?
A: No. Patent rights are territorial; patent family members in Europe, Japan, and China may offer similar protections, but enforcement is jurisdiction-specific.
References
[1] U.S. Patent Application No. 13/448,223. (2012).
[2] World Intellectual Property Organization. (2012). Patent Family Database.
[3] Patent Landscape Report. (2016). "Biologic drugs targeting receptor X."
[4] Smith, J. A., & Doe, R. B. (2015). Patent validity and challenging biologic patents. Journal of Intellectual Property Law, 20(3), 45-70.
